Showing 4681-4690 of 5910 results for "".
- Study Finds Recycling of the Eye’s Light Sensors Is Faulty in Progressive Blindness of Older Adultshttps://modernod.com/news/study-finds-recycling-of-the-eyes-light-sensors-is-faulty-in-progressive-blindness-of-older-adults/2479323/With the National Eye Institute reporting that about 11 million older adults in the US endure age-related macular degeneration (AMD), University of Maryland School of Medicine (UMSOM) researchers are starting to understand what goes wrong in the disease, in order to develop new therapies to tre
- Johnson & Johnson Vision Announces Launch of Tecnis Synergy and Tecnis Synergy Toric II PC-IOLs in US and Canadahttps://modernod.com/news/johnson-johnson-vision-announces-launch-of-tecnis-synergy-and-tecnis-synergy-toric-ii-pc-iols-in-us-and-canada/2479320/Johnson & Johnson Vision announced the availability of Tecnis Synergy and Tecnis Synergy Toric II IOLs in the United States and Canada. These next-generation PC-IOLs combine the best of extended depth of focus and multifocal technologies to deliver the widest range of continuous vision and th
- PanOptica Announces Licensing Agreement with Zhaoke Ophthalmology for the Treatment of Neovascular Eye Diseases in China, South Korea, and Southeast Asiahttps://modernod.com/news/panoptica-announces-licensing-agreement-with-zhaoke-ophthalmology-for-the-treatment-of-neovascular-eye-diseases-in-china-south-korea-and-southeast-asia/2479318/PanOptica announced a licensing agreement with Zhaoke Ophthalmology Limited to develop and commercialize PAN-90806, an investigational topical eye drop for the treatment of neovascular eye diseases, including wet age-related macular degeneration (AMD) and diabetic retinopathy, in China, South Kor
- Gemini Therapeutics Announces Data From Ongoing Phase 2a Study in Patients with GA Secondary to Dry AMDhttps://modernod.com/news/gemini-therapeutics-announces-initial-data-from-its-ongoing-phase-2a-study-of-gem103-in-patients-with-geographic-atrophy-secondary-to-dry-amd/2479317/Gemini Therapeutics announced initial data from its phase 2a ReGAtta study of GEM103 as of May 2021 in patients with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). ReGAtta is a dose escalation trial of GEM103, which is intravitreally administered recombinant huma
- Belkin Laser Appoints Andrew Webb as Chief Commercial Officerhttps://modernod.com/news/belkin-laser-appoints-andrew-webb-as-chief-commercial-officer/2479316/Israel-based medical device company Belkin Laser has announced the appointment of Andrew Webb as Chief Commercial Officer. Under Mr. Webb’s guidance, the company’s commercial and go-to-market strategy will be rolled out in anticipation of a controlled launch in
- ScienceBased Health Announces New Ophthalmology Clinical Advisory Panelhttps://modernod.com/news/sciencebased-health-announces-new-ophthalmology-clinical-advisory-panel/2479314/ScienceBased Health (SBH) announced the formation of its new Ophthalmology Clinical Advisory Panel that will provide insight and recommendations on eye care industry trends and new developments. In addition, it will help guide and support the company’s educational initiatives in the ophthalmology
- Allergan Adds Two Experts to Eye Care Divisionhttps://modernod.com/news/allergan-adds-two-experts-to-eye-care-division/2479311/Allergan has announced two new additions to leadership roles in Allergan Eye Care. E. Randy Craven, MD, FACS, has joined Allergan Eye Care as medical director of the U.S. medical affairs glaucoma organization. A pioneer of minimally-invasive glaucoma surgery, Dr. Craven previously served a
- Oyster Point Announces Enrollment of First Subject in the OLYMPIA Phase 2 Clinical Trial for Patients with Neurotrophic Keratopathyhttps://modernod.com/news/oyster-point-announces-enrollment-of-first-subject-in-the-olympia-phase-2-clinical-trial-for-patients-with-neurotrophic-keratopathy/2479308/Oyster Point Pharma announced enrollment of the first subject in the OLYMPIA phase 2 clinical trial of OC-01 (varenicline) nasal spray for the treatment of Stage 1 Neurotrophic Keratopathy (NK). “This is an exciting milestone as we continue to develop this potentially new tr
- Implandata’s Receives CE Mark for the EYEMATE-SC Biosensor for Remote Glaucoma Carehttps://modernod.com/news/implandatas-receives-ce-mark-for-the-eyemate-sc-biosensor-for-remote-glaucoma-care/2479310/Implandata Ophthalmic Products announced that its EYEMATE-SC biosensor has obtained CE Mark. This device is used in conjunction with the EYEMATE system for digitally enabled remote glaucoma monitoring and management. The patented EYEMATE system is the world’s only clinically-validated pro
- US Looks to Spur Advances in COVID-19 Antivirals With $3.2-Billion Infusionhttps://modernod.com/news/us-looks-to-spur-advances-in-covid-19-antivirals-with-3-2-billion-infusion/2479304/The US Department of Health and Human Services (HHS) said Thursday that it is allocating $3.2 billion toward the discovery, development and manufacturing of antivirals as part of its strategy to support the next-generation of COVID-19 treatments, according to a FirstWord report. “New antivi